Cited by 93Schizophrenia research and treatmentGenomic variations and chromosomal abnormalitiesGenetic Associations and Epidemiology

Further evidence for high rates of schizophrenia in 22q11.2 deletion syndrome

Monks, Stephen, Niarchou, Maria, Davies, Aimée R., Walters, James T.R., Williams, Nigel, Owen, Michael J., van den Bree, Marianne B.M., Murphy, Kieran C.·2014·Schizophrenia Research

Abstract

22q11.2 deletion syndrome (22q11.2DS) is associated with high rates of psychotic disorder, particularly schizophrenia. The deletion is considered to be a biological model for understanding this debilitating psychiatric disorder. It is unclear whether the psychotic manifestations in 22q11.2DS are similar to those in schizophrenia patients without the deletion. Catechol-O-methyltransferase (COMT), a positional candidate gene for schizophrenia, resides within the 22q11.2 region. It remains unknown whether hemizygosity for this gene is associated with risk of psychotic disorder. This study includes 83 adults with 22q11.2DS, 90 non-deleted individuals with schizophrenia, and 316 normal controls. Psychopathology was assessed using the Schedules for Clinical Assessment in Neuropsychiatry, the Schedules for the Assessment of Positive and Negative Symptoms and the Global Assessment Scale. Schizotypy was assessed with the Kings Schizotypy Questionnaire and Oxford Liverpool Inventory of Feelings and Emotions. IQ estimates were also obtained. Adults with 22q11.2DS were genotyped for a number of COMT polymorphisms as well as the Ashkenazi risk haplotype. This study confirms high rates of psychotic disorder (29%) in individuals with 22q11.2DS of which the majority had schizophrenia (22%). There does not appear to be a differential expression of schizophrenic symptom clusters in 22q11.2DS in relation to sporadic schizophrenia, though schizophrenia in 22q11.2DS seems to be less severe in terms of global assessment scores. Psychosis proneness seems to be of genetic origin in 22q11.2DS as individuals with 22q11.2DS without schizophrenia had higher schizotypy scores than normal controls. Finally, COMT was not associated with schizophrenia status or schizotypy.

Integrity signals

Registry

Crossref · 10.1016/j.schres.2014.01.020

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The way clinical phenotypes unfold over development in CNV carriers appears similar to that in idiopathic populations.

    “Results suggest that the developmental course of clinical phenotypic expression of CNV carriers resembles that of idiopathic populations (Monks et al., 2014).”

    From Getting to the cores of autism (2019) · cites this paper as Monks et al., 2014

  • Up to one in four 22q11DS patients develop psychosis, corresponding to about a 20-fold increased risk, and this accounts for 1-2% of schizophrenia cases.

    “Up to one in four 22q11.2DS patients develop psychosis, which correspond to a ~20–fold increase in risk, and accounts for 1–2% of all schizophrenia cases4–6.”

Cites

Flagged first, then by citations

4 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Monks, S., Niarchou, M., Davies, A. R., Walters, J. T. R., Williams, N., Owen, M. J., van den Bree, M. B. M., & Murphy, K. C.
Affiliations
  • Royal College of Surgeons in Ireland (IE)
  • Cardiff University (GB)
Corresponding author
Murphy, Kieran C.
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2014-03
Volume
153
Issue
1-3
Pages
231-236
ISSN
0920-9964 (ISSN-L)
OpenAlex
W2121042474
Cited by
93
References
48
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 11 · 2021: 10 · 2020: 13 · 2019: 8 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 8 · 2014: 1
FWCI
6.81
Type
journal article
Language
en
Open access
closed
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders
  • 22q11 Ireland
  • Max Appeal (UK)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
Keywords
22q11.2 deletion syndrome, schizophrenia
MeSH terms
Adolescent, Adult, Catechol O-Methyltransferase, DiGeorge Syndrome, Female, Genotype, United Kingdom, Humans, Intelligence, Male, Middle Aged, Psychiatric Status Rating Scales, Surveys and Questionnaires, Schizophrenia, Schizotypal Personality Disorder, Statistics, Nonparametric, Polymorphism, Single Nucleotide, Young Adult, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review